Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Quesada, A; Botto, G; Erdogan, A; Kozak, M; Lercher, P; Nielsen, JC; Piot, O; Ricci, R; Weiss, C; Becker, D; Wetzels, G; De Roy, L; PreFER MVP Investigators.
Managed ventricular pacing vs. conventional dual-chamber pacing for elective replacements: the PreFER MVP study: clinical background, rationale, and design.
Europace. 2008; 10(3): 321-326.
Doi: 10.1093/europace/eun035
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Lercher Peter
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- AIMS: Several clinical studies have shown that, in patients with intact atrioventricular (AV) conduction, unnecessary chronic right ventricular (RV) pacing can be detrimental. The managed ventricular pacing (MVP) algorithm is designed to give preference to spontaneous AV conduction, thus minimizing RV pacing. The clinical outcomes of MVP are being studied in several ongoing trials in patients undergoing a first device implantation, but it is unknown to what extent MVP is beneficial in patients with a history of ventricular pacing. The purpose of the Prefer for Elective Replacement MVP (PreFER MVP) study is to assess the superiority of the MVP algorithm to conventional pacemaker and implantable cardioverter-defibrillator programming in terms of freedom from hospitalization for cardiovascular causes in a population of patients exposed to long periods of ventricular pacing. METHODS AND RESULTS: PreFER MVP is a prospective, 1:1 parallel, randomized (MVP ON/MVP OFF), single-blinded multi-centre trial. The study population consists of patients with more than 40% ventricular pacing documented with their previous device. Approximately, 600 patients will be randomized and followed for at least 24 months. The primary endpoint comprises cardiovascular hospitalization. CONCLUSION: The PreFER MVP trial is the first large prospective randomized clinical trial evaluating the effect of MVP in patients with a history of RV pacing.
- Find related publications in this database (using NLM MeSH Indexing)
- Algorithms -
- Australia -
- Canada -
- Cardiac Pacing, Artificial - methods
- Cardiovascular Diseases - physiopathology
- Defibrillators, Implantable -
- Europe -
- Follow-Up Studies -
- Heart Conduction System - physiopathology
- Heart Ventricles - physiopathology
- Humans -
- Middle East -
- Pacemaker, Artificial -
- Prospective Studies -
- Single-Blind Method -